Last reviewed · How we verify
Rivaroxaban 10 Milligrams
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) prevention and treatment, Pulmonary embolism (PE) prevention and treatment.
At a glance
| Generic name | Rivaroxaban 10 Milligrams |
|---|---|
| Sponsor | Ahmed AbdelMoneim Hassan Ali |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) prevention and treatment
- Pulmonary embolism (PE) prevention and treatment
- Acute coronary syndrome
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Abdominal pain
Key clinical trials
- Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure (PHASE3)
- A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants (PHASE1)
- A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection (PHASE3)
- A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19) (PHASE2)
- Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants (PHASE3)
- Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |